Company ProfilePremium

Huabao International Holdings Limited

Company Profile Analysis

Ticker: 0336.HK華寶國際控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Huabao International Holdings Limited - Food & Beverages showcase

Year Founded & Workforce

1996

4,059 Employees

Industry

Food & Beverages
Huabao International Holdings Limited logo

Huabao International Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Huabao International Holdings Limited Overview

Huabao International is a China-centred "taste and scent" platform. It has historically been best known as one of China's leading suppliers of tobacco flavours and reconstituted tobacco leaf (RTL). Since 2020 the group has diversified into food flavours, fragrances, food and health ingredients, aroma chemicals and B2B condiments. It describes this as a "concentric diversification" strategy centred on the taste industry. The group reports four segments: Huabao Technology (formerly F&F and Food Ingredients), Tobacco Raw Materials, Aroma Raw Materials and Condiment. It serves five downstream markets: food and beverage, daily-use chemicals, health, catering and tobacco. The balance sheet is very strong, with roughly RMB5.7bn of net cash and wealth-management products at 30 June 2026. However, reported earnings have been repeatedly hit by goodwill impairments totalling about RMB3.5bn over FY2020–FY2025. Management's equity story now rests on internationalisation (Indonesia RTL, global tobacco majors), innovative tobacco (HNB and oral nicotine), health ingredients and shareholder returns.


Company's own description (FY2025 annual results). The company says it pursues concentric diversification centred on the taste industry, under the philosophy of "green, delicious and healthy". Its stated focus is on high-growth sectors, namely innovative tobacco, health and daily-use chemicals. Its four segments serve food and beverage, daily-use chemicals, the health industry, catering and tobacco, which management describes as large, resilient end markets. In the 1H2026 announcement, management restated the Huabao Technology segment around three businesses: "taste", "nutrition and health", and "scent and care". It described the renaming as a move from "flavours and fragrances manufacturer" to "integrated solutions provider".

Business model. Huabao is overwhelmingly a B2B formulator and manufacturer.

Product sales dominate revenue: No subscription or licensing revenue is disclosed. Value is created through proprietary formulations (flavour and fragrance compounds), process know-how (RTL papermaking and slurry processes, capsule drop-forming) and customer-specific co-development, especially with tobacco customers.

Value-chain position: - In flavours and fragrances, Huabao sits mid-stream. It buys aroma chemicals and natural extracts, some of which it makes in-house through the Aroma Raw Materials segment. It sells compounded flavours to cigarette makers, food and beverage brands and daily-chemical brands.

  • In tobacco materials it supplies RTL and "new materials" (flavour capsules and, historically, filter rods) to cigarette and HNB manufacturers.

  • In condiments (Jiahao, Jiafu) it is closer to the end-user. It sells chicken bouillon, mustard/wasabi, sauces, soup bases and customised compound seasonings to catering operators via distributors and, increasingly, through direct key-account sales.

Customer types: - Chinese state tobacco industrial companies, historically the dominant profit pool.

  • International tobacco majors. The 1H2026 filing says Huabao Technology has entered the supply chains of the world's top three tobacco customers.

  • Multinational and domestic food brands. Mondelez, Nestlé, Bright Dairy, Dali, Dayao and Orion are named in filings.

  • New-style tea chains.

  • Daily-chemical brands and hotels, including Atour Hotel, Li Zi, Lan Ju, Yu Mei Jing and Libai.

  • Health and nutrition brands, including New Hope, Yum China, Nuotelande and WARMSANTA.

  • Chain and SME restaurants, industrial food factories and condiment distributors. Jiahao had more than 650 Tier-1 distributors at end-2023.

Revenue mix (FY2025). Huabao Technology (F&F and food ingredients) was 37.8%, Condiment 23.9%, Aroma Raw Materials 23.2% and Tobacco Raw Materials 15.2%. In 1H2026 the mix was 38.2%, 26.4%, 24.8% and 10.6% respectively.

Independent characterisation. Huabao is in transition. Until about 2021, it was effectively a high-margin, quasi-regulated supplier to China's tobacco monopoly. Group gross margin was 63.4% in FY2020 and the F&F segment margin was about 60%. That profit pool has eroded structurally. Domestic tobacco purchasing policies changed, traditional RTL is in oversupply, and capsule prices have fallen. The group gross margin fell to 40.8% by FY2025. Management has used its cash pile to buy into lower-margin but larger and faster-growing categories: condiments, food ingredients, health ingredients and fragrances. It is also building international tobacco capacity in Indonesia and Paraguay. The acquired businesses have produced the repeated goodwill write-downs, notably Jiahao (2020, 2025), Shanghai Yifang, Yancheng Chunzhu and Jiangxi Xianghai. The tobacco-legacy CGUs were also written down (RTL in 2021, 2022 and 2024; tobacco flavours in 2024). As a result, the business now looks more like a diversified mid-cap Chinese ingredients company with a large net cash position, and less like a tobacco-flavour franchise.

Strategy

Stated strategy (FY2025 AR and 1H2026). The core is "concentric diversification" centred on the taste industry, with "green, delicious and healthy" as the guiding philosophy. A new three-year strategic plan began in 2026. Management describes 2026 as both a pivotal year for that plan and the group's 30th anniversary, and says it is approaching the plan with a "starting from zero" mindset.

Seven management priorities for 2026 (FY2025 outlook):

  1. Drive execution through clearly defined priority tasks.

  2. Use procurement as the entry point for cost reduction.

  3. Roll out AI across the whole workforce.

  4. Maintain strict compliance and advance ESG.

  5. Improve collaboration between subsidiaries and segments.

  6. Pursue organic growth and M&A as twin engines.

  7. Strengthen capital-markets communication and reward shareholders through sustained cash dividends and buybacks.

Medium-term financial targets / guidance. Not publicly disclosed. The company gives no numeric revenue, margin or EPS guidance. The 1H2026 outlook speaks of a "solid foundation for achieving full-year targets" without quantifying them.

Products & Services

Pricing models are not publicly disclosed for any line. All products are sold on a B2B contract or purchase-order basis unless noted.

Huabao Technology segment

Product line / brandDescription & capabilitiesTarget customerLatest disclosed development (year)
Tobacco flavours (taste)Custom flavour formulations for cigarettes. HNB-specific flavours designed for stable, layered aroma release across heating temperatures. Oral-tobacco flavour systems.Chinese tobacco industrial companies; international tobacco majors (filings state entry into the top three global tobacco companies' supply chains)Mass delivery to overseas customers (2025); HNB-specific flavours (1H2026)
Food flavours — savoury (taste)Meat-product and "wet and spicy" snack flavours; biscuit seasonings; savoury compound flavours. Tianjin lab focused on northern savoury tastes.Snack, meat, biscuit manufacturers; supermarket private labelMultiple new biscuit flavours (2025)
Food flavours — sweet / heat-resistant (taste)Microcapsule paste flavours with temperature resistance. Potato and ginger microcapsule powders for baking and puffed foods. Regional flavours such as pandan and coconut.Bakery, puffed food, dairy, beverage makersPandan and coconut launches (2023)
Natural flavours (taste)More than ten certified natural flavour products. Industry-first CQC Food Ingredients Natural Degree certificate. Developed with the "Shanghai Natural Food Center".Multinational and domestic food brands; export marketsNatural certifications (2025–1H2026)
Compound flavour products (taste)Sweet and savoury compound flavour systems; mid-to-high-end food ingredients; local speciality flavour seriesBrand owners, supermarketsPortfolio build-out (1H2026)
New-style tea beverage ingredientsTaiwanese-style dried plum, honey grapefruit juice, frozen grape juice, canned red beans. Halal-certified for overseas expansion.Freshly-made tea chainsEntry into the segment (2025)
Fruit ingredients / popping boba (nutrition & health; Shanghai Yifang)Natural fruit products, jams, fruit pieces. "IceFire Magic Ball" popping boba. Freeze-resistant boba for ice cream, liquid-filled high-oil boba, heat-resistant boba for bakery. Food-grade boba for nicotine pouches developed for an international tobacco company.Mondelez, Orion, beverage, bakery and dessert makers; tobacco company (nicotine-pouch boba)Nicotine-pouch boba validated, with commercial breakthrough expected in 2026
Functional / nutritional ingredients (Better World Naturals; Shandong and Jiangxi Jiacui bases)Calcium citrate, nano-calcium, functional emulsions, fish-oil nanoemulsion, nanocrystalline curcumin, vitamins, minerals, natural extracts. Delivered as one-stop application solutions.Sports nutrition, dairy, beverage, functional food brands (New Hope, Yum China, Nuotelande, WARMSANTA)Large-scale delivery of nano-calcium and fish-oil nanoemulsion (1H2026); Korean contracts (2026)
Natural meat extracts / peptide flavouring (Hunan Jiapin)Small-molecule peptide flavouring; bone extracts, bone materials, animal and plant extractsFood processors, condiment makersConsolidated from Jun 2025
Daily-use fragrances (scent and care; Amber (Xiamen))Fragrances for fabric care, personal care, perfume, cosmetics, home fragrance, household cleaning, incense and disinfection, pet care, oral care. Eucalyptol LTB; microencapsulated fragrances; functional "emotional" fragrances with soothing, refreshing and anti-fatigue claims based on brainwave and micro-expression research.Domestic daily-chemical brands (Li Zi, Lan Ju, Yu Mei Jing, Libai); hotels (Atour); distributors in Africa, Vietnam and ThailandOriginal-scent series launched (1H2026); AI-GCMS platform under test

Tobacco Raw Materials segment

Product lineDescription & capabilitiesTarget customerLatest disclosed development
Traditional RTL (papermaking process)Reconstituted tobacco leaf used as an additive in conventional cigarettes. Guangdong Jinye is one of the few STMA-designated bases.Chinese tobacco industryVolumes declining because of procurement policy changes. The industry has about 180,000 t of annual capacity against weaker demand (FY2021 filing).
Innovative / HNB RTLRTL tailored for heat-not-burn sticks, made by drying, slurry and granule techniques. The Indonesian base has three lines and about 3,000 t of capacity.International tobacco majors; regional tobacco companiesIndonesian line running at full load from late 2Q2026; master supply agreement being renewed (1H2026)
Flavour capsules (tobacco new materials)Breakable flavour capsules for cigarettes and HNB. AI optical sorting machine in use.Tobacco customers in nearly 20 countries (Asia, South America, Middle East, Eastern Europe; Argentina added in 2026)Paraguay capsule factory initiated (1H2026)
Food and probiotic capsulesCapsule technology redeployed to food and probiotic controlled-release uses. Patent covers gastrointestinal controlled-release probiotic capsules.Food, beverage, probiotic makersPatent granted (2023)
Filter rods (divested)Hunan Jishou filter rods, including binary cooling filters for HNBDomestic tobaccoDisposed of in 2025

Aroma Raw Materials segment

ProductDescriptionTarget customerNotes
Ethyl maltolSynthetic sweet aroma enhancerFood, beverage, tobacco, daily-chemicalVolume growth in 1H2026
Natural citralNatural citrus aroma chemicalF&F housesVolume growth in 1H2026
Leaf alcoholsGreen-note aroma chemicalsF&F housesVolume growth in 1H2026
FuranoneCaramel / fruity aroma chemicalFood flavoursVolume growth in 1H2026
Natural lactonesCreamy and fruity notesFood and dairy flavoursVolume growth in 1H2026
Low-carbon alcohols, esters, acids, aldehydes (Yancheng Chunzhu)Basic food-flavour chemicals, mainly exported to Europe, the US, Southeast Asia and JapanFood and daily-chemical F&F houses, feed, pharmaGoodwill partially impaired (2023)
Furan-derived chemicals (Jiangxi Xianghai)Fine chemicals; patent on chloroethane recovery in alpha-ethyl furan carbinol production. Design capacity 8,500 t.F&F, chemicalsGoodwill fully impaired (2023)

Condiment segment

Product / serviceDescriptionTarget customerNotes
Chicken bouillon (liquid), chicken powder, chicken essence (Jiahao)Umami-enhancing core products with regional flavour variantsSME restaurants via distributors; chainsCore of the Jiahao franchise
Wasabi / mustard pasteFlavour-enhancing productRestaurants (Japanese cuisine, seafood)Core product
Concentrated fruit juices (cooking), functional soy sauce, gravy, saucesFlavour enhancersRestaurantsPatent on inhibiting browning in concentrated citrus juice (2023)
Commercial soup basesStandardised soup bases for chainsChain restaurants; retail soup-base businessOne of three "core services" (2026)
Intelligent kitchen-robot sauces ("robot + sauce")Sauces designed for kitchen robots, linked to an investment in a kitchen-robot companyChains seeking automationGrowth reported in 1H2026
Customised flexible compound seasoningsB2B custom compound seasoningsChains, industrial factoriesGrowth reported in 1H2026
Jiangsu Jiafu compound condiments and spicesRetail OEM, catering and industrial channels; overseas customisation; hot-pot basesChain caterers, industrial clients, overseas OEMNew factory construction began end-July 2026

Financial Narrative

Income statement

Notes:

  • FY2021 and FY2023 EBITDA are computed as operating profit plus segment depreciation and amortisation. FY2023 agrees with the RMB695.6m comparative in the FY2024 announcement.

  • FY2024 and FY2025 EBITDA are as reported.

  • FY2021–FY2023 adjusted EBITDA is derived from the company's disclosed "EBITDA margin" (excluding share-based compensation and goodwill impairment) of 43.5%, 32.2% and 22.9%. FY2024–FY2025 figures are the company's Non-HKFRS EBITDA.

  • FY2020 comparatives: revenue RMB3,854.1m; attributable profit RMB418.4m; DPS HK15.0c.

Margins and growth

Revenue CAGR FY2021–FY2025 was −2.7%. Over FY2020–FY2025 it was −2.0%.

Balance sheet

At 30 June 2026 the position was as follows:

  • Cash: RMB4,292.9m

  • Wealth-management products: RMB1,580.3m

  • Borrowings: RMB126.4m

  • Net cash including WMP: about RMB5,746.8m

  • Equity attributable: RMB11,293.3m

  • Total assets: RMB13,970.9m

Cash flow

Blank cells mean the figure was not available in the results announcements retrieved; it appears in the full annual reports. FY2023 and FY2025 announcements give only investing-activity totals: net cash used of RMB2,604.7m in FY2023 and RMB925.8m in FY2025, both dominated by WMP purchases. FY2022 net investing inflow was RMB1,244.0m. 1H2026 OCF was RMB93m, against RMB214m in 1H2025. Buybacks in 1H2026 totalled HK$24.1m for 6.286m shares.

Commentary on trends, inflections and drivers

Revenue. Revenue has been broadly flat to down in nominal terms for five years. It peaked at RMB3.88bn in FY2021 and bottomed at RMB3.31bn in FY2023. Composition has changed sharply.

  • F&F (tobacco flavours) revenue fell by RMB609m between FY2021 and FY2025. The FY2023 and FY2025 filings attribute this to changing demand from domestic tobacco customers and tougher competition.

  • Condiments, aroma chemicals and (from FY2025) international tobacco materials together added about RMB215m over the same period.

  • The 1H2026 rebound (+15.9%) is the strongest growth in more than five years. However, it is partly inorganic, coming from the consolidation of Jiangsu Jiafu (from August 2025) and Hunan Jiapin (from June 2025).

Gross margin. Gross margin fell 22.6 points from FY2020 (63.4%) to FY2025 (40.8%), and stayed at 40.8% in 1H2026. This is the single most important trend. It reflects mix dilution away from very high-margin tobacco flavours and traditional RTL, price competition in capsules and aroma chemicals, and inventory and PP&E impairments booked within cost of sales.

Operating line. The operating line is volatile because of goodwill impairments: RMB495.5m (FY2020), RMB293.3m (FY2021), RMB1,507.7m (FY2022), RMB56.5m (FY2023), RMB630.9m (FY2024) and RMB488.4m (FY2025), about RMB3.47bn in total. Excluding impairments and share-based compensation, the Non-HKFRS operating profit fell from about RMB1,408m in FY2021 (impairment-adjusted) to RMB223m in FY2025. This shows the underlying earnings decline is real and not only an accounting effect.

Cost structure. Several cost lines have moved materially:

Administrative expenses: rose from 21.7% of revenue in FY2021 to 27.8% in FY2025. Share-based compensation rose to about RMB96m in FY2025, against RMB49m in FY2024.

Selling and marketing expenses: rose to 13.1% of revenue in FY2025 (from 7.5% in FY2021) as the group built overseas sales teams.

1H2026 operating leverage: Administrative expenses fell to 25.3% of revenue and selling expenses to 10.3%.

Below the line. Finance income (RMB98m in FY2025) and government grants (RMB90m) are meaningful supports to profit. Both fell in 1H2026: finance income was RMB25m and grants RMB11m. This is why attributable profit fell 11.7% in 1H2026 despite higher operating profit.

Balance sheet. The balance sheet is exceptionally liquid. Cash plus WMP has been RMB6.2–6.8bn at every year-end since FY2021. Gross debt has fallen from RMB2.71bn (FY2020) to RMB0.13bn (June 2026), and all of it is short-term RMB borrowing. Intangible assets have almost halved (RMB6,226m in FY2020 to RMB3,148.6m in FY2025) as goodwill was written down. This lowers the risk of future impairments, but RMB3.1bn of intangibles remain, much of it related to Jiahao.

Working capital. Working capital efficiency has improved. The cash conversion cycle shortened from 243 days (FY2023) to 190 days (FY2025), and inventory days fell to 142 in 1H2026. Operating cash flow conversion has been strong relative to reported losses: FY2025 OCF of RMB826m compares with Non-HKFRS profit of RMB179m.

Shareholder returns. The group has paid dividends, mostly special dividends, in every year including loss years. FY2025 total DPS was HK9.9c, and dividends paid totalled RMB277.5m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Huabao Technology / F&F & Food ingredients (CNY Mn)

1,926.71,877.31,464.41,339.01,317.5

Tobacco raw materials (CNY Mn)

565.4454.3464.7467.7528.8

Aroma raw materials (CNY Mn)

714.0924.3624.7791.5807.0

Condiment (CNY Mn)

676.5573.1754.1774.6831.2

Others (CNY Mn)

0.00.00.00.50.1

Group revenue (CNY Mn)

3,882.73,829.03,307.83,373.33,484.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment — Huabao Technology / F&F

SegmentFY2021FY2022FY2023FY2024FY2025

Huabao Technology / F&F (CNY Mn)

1,104.1824.1405.5-300.555.4

Tobacco raw materials (CNY Mn)

-80.1-237.590.8-82.122.8

Aroma raw materials (CNY Mn)

59.179.5-83.422.878.9

Condiment (CNY Mn)

136.9-1,116.9116.897.6-409.1

Unallocated / others (CNY Mn)

-105.5-157.1-151.6-139.7-108.8

Group operating profit (CNY Mn)

1,114.5-608.0378.1-401.9-360.9

Segment Margins & Growth (%)

SegmentFY2021FY2022FY2023FY2024FY2025

Huabao Technology / F&F margin (%)

57.343.927.7-22.44.2

Tobacco raw materials margin (%)

-14.2-52.319.5-17.64.3

Aroma raw materials margin (%)

8.38.6-13.42.99.8

Condiment margin (%)

20.2-194.915.512.6-49.2

Segment Margins & Growth (%) and Revenue by Segment (%)

SegmentFY2021FY2022FY2023FY2024FY2025

Huabao Technology / F&F YoY growth (%)

-7.6-2.6-22.0-8.6-1.6

Tobacco raw materials YoY growth (%)

-9.0-19.72.30.713.1

Aroma raw materials YoY growth (%)

11.829.5-32.426.72.0

Condiment YoY growth (%)

34.6-15.331.62.77.3

Huabao Technology / F&F share of revenue (%)

49.649.044.339.737.8

Tobacco raw materials share of revenue (%)

14.611.914.013.915.2

Aroma raw materials share of revenue (%)

18.424.118.923.523.2

Condiment share of revenue (%)

17.415.022.823.023.9

Segment Revenue

Segment1H2025 revenue1H2026 revenueYoY %1H2025 result1H2026 result

Huabao Technology

595.7717.320.418.8105.8

Tobacco raw materials

238.4199.3-16.431.34.2

Aroma raw materials

405.4465.614.961.738.0

Condiment

381.6495.829.938.947.7

Others/unallocated

0.00.1—-28.6-52.2

Group

1,621.21,878.115.9122.2143.4

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

3,882.73,829.03,307.83,373.33,484.7

Gross profit (CNY Mn)

2,296.71,877.61,469.41,441.41,423.1

Goodwill impairment (CNY Mn)

293.31,507.756.5630.9488.4

Operating profit (CNY Mn)

1,114.5-608.0378.1-401.9-360.9

EBITDA, operating profit + D&A (CNY Mn)

1,391.6-277.7695.6-69.7-8.4

Adjusted EBITDA, company non-GAAP (CNY Mn)

1,689.01,233.0757.5624.1575.7

Profit before tax (CNY Mn)

1,147.4-720.2415.9-402.4-286.8

Profit for the year incl. NCI (CNY Mn)

895.8-901.1290.5-458.9-405.5

Net profit attributable to shareholders (CNY Mn)

675.1-1,054.5233.6-385.5-388.8

Basic EPS (MYR Bn cents)

21.70-32.657.23-11.94-12.04

Diluted EPS (MYR Bn cents)

21.70-32.657.23-11.94-12.04

Total DPS for the year (HK cents)

8.408.488.508.509.90

R&D expense (CNY Mn)

250.8266.2253.2245.2287.0

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

59.249.044.442.740.8

Operating margin (%)

28.7-15.911.4-11.9-10.4

EBITDA margin, reported basis (%)

35.8-7.321.0-2.1-0.2

Adjusted EBITDA margin (%)

43.532.222.918.516.5

Net margin, attributable (%)

17.4-27.57.1-11.4-11.2

Revenue growth YoY (%)

0.7-1.4-13.62.03.3

R&D as % of revenue (%)

6.57.07.77.38.2

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

18,025.116,619.016,002.115,002.114,390.3

Cash and bank balances (CNY Mn)

3,553.44,748.02,539.55,562.23,601.3

Bank wealth-management products at FVPL (CNY Mn)

3,256.51,594.33,847.7649.52,646.8

Short-term borrowings (CNY Mn)

962.8677.7419.3194.0146.9

Long-term borrowings (CNY Mn)

0.00.036.00.00.0

Total debt (CNY Mn)

962.8677.7455.3194.0146.9

Net debt, debt minus cash excl. WMP (CNY Mn)

-2,590.6-4,070.3-2,084.2-5,368.2-3,454.4

Net debt incl. WMP (CNY Mn)

-5,847.1-5,664.6-5,931.9-6,017.7-6,101.2

Equity attributable to shareholders (CNY Mn)

13,884.712,650.912,480.412,078.511,378.6

Total equity incl. NCI (CNY Mn)

15,718.814,557.414,271.113,720.413,036.3

Intangible assets incl. goodwill (CNY Mn)

5,847.34,322.74,188.03,462.23,148.6

Inventories (CNY Mn)

897.21,020.0994.6893.3894.8

Current assets (CNY Mn)

8,872.88,699.18,358.08,163.58,148.6

Current liabilities (CNY Mn)

2,133.91,754.91,382.51,129.01,202.6

Working capital / net current assets (CNY Mn)

6,738.96,944.16,975.47,034.56,946.0

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

1,413.2——679.7825.9

Capex, PP&E and intangibles (CNY Mn)

412.6————

Free cash flow, OCF minus capex (CNY Mn)

1,000.6————

Dividends paid to shareholders (CNY Mn)

394.7—252.3—277.5

Dividends paid to NCI (CNY Mn)

206.1—184.0—42.4

Share buybacks (CNY Mn)

0.00.00.0—0.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, attributable NI ÷ average attributable equity (%)

5.2-7.91.9-3.1-3.3

ROA, attributable NI ÷ average total assets (%)

3.8-6.11.4-2.5-2.6

ROIC, analyst estimate, 25% notional tax, cash-adjusted capital (%)

8.5-5.13.4-3.9-3.9

Current ratio (x)

4.164.966.057.236.78

Debt / attributable equity, company definition (%)

6.95.43.61.61.3

Net debt / adjusted EBITDA (x)

-1.53-3.30-2.75-8.60-6.00

Interest coverage, operating profit ÷ finance costs (x)

13.7-16.015.2-19.1-17.2

Asset turnover, revenue ÷ average total assets (x)

0.220.220.200.220.24

Trade receivable days (company-reported)

8789978183

Inventory days (company-reported)

199177197176156

Trade payable days (company-reported)

6553514749

Cash conversion cycle (days)

221213243210190

Geographic Revenue

SegmentDomestic trend (FY2025–1H2026)International trend (FY2025–1H2026)

Huabao Technology

Tobacco flavours down; food flavours, tea and health up

Rapid overseas fragrance growth; Indonesia food complex due 2H2026; Korean health contracts

Tobacco raw materials

Traditional RTL declining; filter rods divested

Capsules in about 20 countries; Indonesian RTL at full load; Paraguay plant initiated; Middle East disruption in 1H2026

Aroma raw materials

Price competition

Indonesia localisation; North America, SE Asia and Europe distributors

Condiment

SME catering weak; key accounts growing

Jiahao Indonesia project approved; Jiafu overseas OEM

Share Price & Returns

Reference pointPrice (HKD)Source

8 Dec 2021 (pre-placing close)

20.30

FY2021 announcement

Dec 2021 placing price

17.88

FY2021 announcement

Feb 2026 buyback range

4.42–4.70

1H2026 announcement

2 Feb 2026 (after a more than 10% fall)

4.58

etnet

25 Mar 2026 (after a more than 10% rise)

4.53

etnet

Apr 2026 (etnet quote)

4.60

etnet

May–Jun 2026 buyback range

3.18–3.88

1H2026 announcement

31 Jul 2026

3.30

etnet

26 Aug 2026

3.255

etnet

Per-Share Data and Share Count (millions)

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (HK cents)

8.408.488.508.509.90

Weighted average shares (millions)

3,111.93,229.93,229.93,229.93,229.9

Valuation Snapshot

MultipleValueBasis

P/E (TTM, attributable)

Not meaningful (loss)

TTM attributable NI about −RMB403m

P/E (TTM, Non-HKFRS profit incl. NCI)

About 46x

TTM Non-HKFRS profit about RMB199m

P/B

About 0.81x

Attributable equity RMB11,293m

EV

About RMB5.0bn

Market cap + NCI − net cash (incl. WMP)

EV / Sales (TTM)

About 1.3x

TTM revenue RMB3,742m

EV / adjusted EBITDA (TTM)

About 8.1x

TTM Non-HKFRS EBITDA RMB621m

Dividend yield (FY2025 DPS)

About 3.0%

HK9.9c ÷ HK$3.255

Analyst Conclusions

Management guidance. There is no numeric guidance. The 1H2026 outlook commits to allocating resources to internationalisation, the health industry, innovative tobacco and high-potential customers. It also commits to accelerating Indonesian ramp-up and overseas plants, deepening joint R&D with global tobacco majors, building health-ingredient ODM capability and internationalising condiments. Management says 1H2026 laid a "solid foundation" for full-year targets, which are not quantified.

Consensus growth expectations. Not publicly verified.

Bull case

  1. Growth inflection with operating leverage. 1H2026 revenue rose 15.9%, adjusted operating profit rose 19.2%, and administrative and selling expense ratios fell by 3.8 and 1.5 points respectively. If this continues, FY2026 adjusted operating profit could recover towards the FY2024 level of RMB292m or above.

  2. Deep value with downside protection. The shares trade at about 0.8x book. Net cash including WMP of about RMB5.7bn is roughly 63% of market capitalisation, and EV/adjusted EBITDA is about 8x. A HK$500m buyback and a yield of about 3% support the shares.

  3. Innovative tobacco optionality. A qualified Indonesian HNB-RTL base, supply-chain entry with the top three global tobacco companies, nicotine-pouch boba and possible Chinese national HNB standards could restore a high-margin growth engine. A collected RMB450.6m arbitration award would be a further one-off upside.

Bear case

  1. Structural margin decline. Gross margin has fallen every year from 63.4% (FY2020) to 40.8%, and it did not improve in 1H2026. The high-margin domestic tobacco profit pool is shrinking permanently.

  2. Capital allocation record. About RMB3.5bn of goodwill impairments and the failed Shanghai Yifang guarantees undermine confidence in the "organic plus M&A" strategy. RMB3.1bn of intangibles remains, much of it in the Jiahao CGU, where growth assumptions were cut again.

  3. Governance and earnings quality. The family controls about 71%. The 2022–23 investigations, persistent share-based compensation (about RMB88m in 1H2026), reliance on finance income and grants, and RMB1.35bn of idle IPO proceeds all warrant a discount.

Key catalysts and monitorables (next 12 months)

  • FY2026 results (around Mar 2027), including any further Jiahao impairment test outcome

  • Indonesian RTL master supply agreement renewal and new international customer conversions

  • Recovery of Middle East tobacco customer demand

  • Finalisation of China's heated-cigarette and nicotine-pouch national standards

  • Enforcement and collection of the Shanghai Yifang award

  • Pace of buyback execution against the HK$500m authorisation

  • Start-up of the Indonesian food complex (2H2026) and the Paraguay capsule plant

  • Health base ramp-up (Shandong, Jiangxi) and the New Zealand decision

  • Gross margin trajectory, and whether it stabilises above 40%

  • Deployment of the RMB889.6m special account of unallocated IPO proceeds

Concluding analyst verdict

Huabao International is a cash-rich company in the middle of an uncomfortable transformation. For a decade it earned unusually high returns as a supplier to China's tobacco monopoly. That franchise is fading. Group gross margin has fallen more than 22 points since FY2020, F&F revenue has dropped by a third, and the tobacco-legacy CGUs have been repeatedly written down. Management's response has been to buy growth in condiments, ingredients and fragrances. The results have been poor. Roughly RMB3.5bn of goodwill has been written off in six years, and the Shanghai Yifang deal ended in arbitration.

The 1H2026 results are the first credible sign that the redesigned portfolio can grow. Revenue rose 15.9%, adjusted operating profit rose 19%, and cost ratios fell in a measurable way. Strategically, the most valuable asset may be the least visible: a qualified, overseas HNB-RTL and capsule platform supplying the world's largest tobacco companies, backed by an active patent programme. If China opens its domestic HNB market under the new national standards, Huabao is one of the few local suppliers with both domestic relationships and international qualifications.

Valuation already discounts much of the pessimism. The shares trade at about 0.8x book and about 8x adjusted EV/EBITDA, with net cash plus WMP equal to roughly two-thirds of market capitalisation, and the company is paying special dividends and buying back stock. The discount also reflects real problems: weak capital allocation, a family-controlled board with a recent history of investigations, low reported ROE and margins that are still falling.

Verdict: a value-with-optionality situation rather than a quality compounder. We would treat the stock as a balance-sheet-protected recovery candidate. Upgrading conviction would require three things: gross margin stabilising at or above 40%, a full year without impairments, and visible growth in international tobacco revenue. Failure on any of these would point to a continuing value trap.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / notesPrior roles / background

Ms. CHU Lam Yiu (朱林瑤)

Chairlady, Executive Director, Chair of Nomination Committee

Founder-controller. CEO from 9 Apr 2013 to 7 Jan 2026. Ultimate interest about 71% (Mar 2024).

Under PRC residential surveillance Jan 2022–Jul 2023; freed of all bail conditions 14 Jul 2023

Mr. XIA Liqun (夏利群)

CEO (from 7 Jan 2026), Vice Chairman, President, Executive Director, Remuneration Committee member

Long-standing Vice Chairman and President

—

Mr. LAM Ka Yu (林嘉宇)

Co-Chairman, Vice President, Executive Director

Son of Ms. Chu; director of Huabao Technology

Subject to the same 2022 investigation; bail conditions removed Jul 2023

Mr. POON Chiu Kwok (潘昭國)

Vice President, Company Secretary, Executive Director

Signs most HKEX announcements

—

Ms. LAM Ka Yan (林嘉炘)

Executive Director

Daughter of Ms. Chu

—

Ms. CHOY Man Har (蔡文霞)

Executive Director; Deputy CFO (per 2023 disclosure)

—

Arrested by ICAC on 5 Jul 2023, released on bail without charge

Mr. LEE Luk Shiu (李祿兆)

INED; Chair of Audit Committee

——

Mr. Jonathan Jun YAN

INED; Audit Committee

——

Mr. HOU Haitao (侯海濤)

INED; Audit Committee

Joined after FY2021; replaced Ms. MA Yunyan

—

Board & Management Changes

DateChangeContext

Jan 2022 – Jul 2023

Chair/CEO and Co-Chairman under PRC investigation; duties shared by the Co-Chairman, Vice Chairman and President, and the Company Secretary

FY2023 announcement

Jul 2023

ICAC arrest of ED Choy Man Har (released without charge)

FY2023 announcement

~2022–2023

INED Ma Yunyan replaced by Hou Haitao

Board lists FY2021 vs FY2023

7 Jan 2026

Xia Liqun appointed CEO; Chu Lam Yiu remains Chairlady

FY2025 announcement

Competitive Landscape

Competitors by Segment

SegmentCompetitorListingApprox. scaleRelative positioning

Flavours & fragrances

Givaudan

SIX: GIVN

About CHF7bn revenue

Global leader; far larger, broader, higher R&D spend

Flavours & fragrances

dsm-firmenich

Euronext: DSFIR

About EUR12–13bn

Global leader in taste, texture and health

Flavours & fragrances

IFF

NYSE: IFF

About USD11bn

Global leader; strong China presence

Flavours & fragrances

Symrise

XETRA: SY1

About EUR5bn

Global; strong in pet food and aroma molecules

Flavours & fragrances

Takasago

TSE: 4914

About JPY200bn

Asian F&F major

Flavours & fragrances

Sensient Technologies

NYSE: SXT

About USD1.5bn

Colours and flavours

Flavours & fragrances (China)

Shanghai Apple Flavor & Fragrance

SSE: 603020

—

Domestic F&F competitor

Tobacco flavours / materials (China)

China Boton Group

HKEX: 3318

—

Direct competitor in tobacco flavours and HNB

Tobacco materials / HNB

Shenzhen Jinjia Group

SZSE: 002191

—

Tobacco packaging and HNB materials

Aroma chemicals (maltol etc.)

Anhui Jinhe Industrial

SZSE: 002597

—

Leading maltol producer; price competition

Condiments (chicken bouillon)

Totole (Nestlé), Knorr (Unilever)

—

Large MNC brands

Brand leaders in chicken essence and bouillon for catering

Condiments (broad)

Foshan Haitian

SSE: 603288 / HKEX

Largest Chinese condiment maker

Scale leader; soy sauce focus

Compound condiments

Yihai International, Baoli/others

HKEX: 1579

—

Hot-pot and compound seasonings

Peer Comparison FY2025

MetricHuabao (FY2025)Givaudan (FY2024, approx.)Symrise (FY2024, approx.)IFF (FY2024, approx.)

Revenue

RMB3.48bn (about USD0.48bn)

About CHF7.4bn

About EUR5.0bn

About USD11.5bn

Revenue growth

+3.3%———

Gross margin

40.8%———

Adjusted EBITDA margin

16.5%———

R&D % of revenue

8.2%———

Company Snapshot

$484.7M

Revenue

4,059

Employees

1996

Founded

Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet. Cash of RMB4.29bn plus WMP of RMB1.58bn against borrowings of RMB0.13bn at 30 Jun 2026. The debt ratio is 1.1% (1H2026 announcement).
  • Strong cash generation despite reported losses. FY2025 OCF was RMB826m (+21.5%) against an attributable loss of RMB389m (FY2025 AR).
  • Qualified international HNB supply position. Indonesian 3,000 t RTL base at full load. The company says it is in the supply chains of the top three global tobacco companies (1H2026).
  • Growing IP portfolio in innovative tobacco. 178 patent applications and 118 PCT filings in FY2025 (FY2025 AR).
  • Diversified revenue. No segment above 39% of revenue in 1H2026. Condiment and aroma together were 51%.
  • Consistent shareholder returns. Dividends paid in every year including loss years (FY2025 DPS HK9.9c), plus a HK$500m buyback authorisation.

Weaknesses

  • Structural gross-margin erosion. From 63.4% (FY2020) to 40.8% (FY2025 and 1H2026).
  • Poor M&A capital allocation. Goodwill impairments of about RMB3.47bn over FY2020–FY2025. The Shanghai Yifang guarantees were missed by RMB83m, RMB121m and RMB144m in 2022–2024.
  • Rising overhead. Administrative expenses rose to 27.8% of revenue in FY2025 from 21.7% in FY2021. Share-based compensation was about RMB96m in FY2025.
  • Governance concentration. The founder holds about 71%. Three of nine directors are from one family. INEDs are at the one-third minimum.
  • Idle capital. About RMB1.35bn of Huabao Technology IPO proceeds is still unutilised eight years after the IPO. The TechInno Project has been delayed five times, now to 2030.
  • Low returns. ROE was −3.3% in FY2025 and averaged about −1.4% over FY2021–FY2025.

Opportunities

  • Global HNB and oral nicotine growth. HNB was USD43bn in 2025 (+13.4%) and oral nicotine USD9.2bn (+45.7%) (Euromonitor, cited in 1H2026).
  • Opening of China's domestic HNB / nicotine-pouch market. Mandatory national standards entered the drafting phase after 7 May 2026.
  • Health ingredients ODM. China's dietary supplement market is RMB312bn. New Shandong, Jiangxi and New Zealand bases are coming.
  • Compound condiments growth. 9.8% CAGR to RMB208bn by 2030. Jiafu adds chain-catering and export OEM.
  • Recovery of the RMB450.6m arbitration award (Feb 2026), which would equal roughly 4% of market capitalisation if collected.
  • Deployment of net cash. Buybacks at about 0.8x book or value-accretive M&A.

Threats

  • Domestic tobacco policy. Changed procurement caused traditional RTL and tobacco-flavour declines (FY2025 AR).
  • Geopolitical disruption. Middle East conflict halted key customers' production in 1H2026, and tobacco segment profit fell 86.7%.
  • Catering SME weakness. Jiahao CGU revenue fell 5.3% in FY2025, and forecast growth assumptions were cut to 6.9–11.3%. Further impairments are possible against about RMB3.1bn of intangibles.
  • Price competition. In aroma chemicals, 1H2026 segment profit fell 38.4% despite +14.9% revenue.
  • Tightening regulation. WHO FCTC COP11 (Nov 2025) and the EU TPD constrain innovative tobacco.
  • Lower interest rates and fewer grants. Finance income fell to RMB25m in 1H2026 from RMB57m, and grants to RMB11m from RMB52m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jun 2025Control of Hunan Jiapinjiawei completedAdds natural meat-extract and peptide technology; boosted 1H2026 segment revenue
Jun 2025 (approx.)1H2025 impairment-free period: 1H2025 attributable profit RMB118.1m, up 298% YoYRecovery from 1H2024's RMB29.7m
Aug 202551% of Jiangsu Jiafu acquired for RMB159mCondiment growth driver; +29.9% segment revenue in 1H2026
Aug 2025Company share options grantedRaised share-based compensation in FY2025–2026
2025Termination of Huabao Flavours' first-phase restricted share plan, with accelerated vestingAbout RMB90m administrative share-based compensation in FY2025
Aug 20251H2025 results; interim dividend HK1.2c plus special dividend HK3.2cSteady returns policy
2025Stake increase in Amber (Xiamen)Fragrance platform consolidation
2025Disposal of Jishou YancaiExit from domestic filter rods
2025Indonesian RTL base fully operational with three lines; mass delivery to international majorsKey international milestone
2025178 patent applications and 118 PCT filingsIP moat building
Oct 20251H2025 dividends paid (HK$142m)—
Nov 2025WHO FCTC COP11 in Geneva discusses innovative tobacco regulationRegulatory backdrop
7 Jan 2026Xia Liqun appointed CEO; Chair and CEO roles separatedGovernance improvement
28 Jan 2026Profit warning: FY2025 pre-tax loss of RMB263–343m including RMB470–530m Jiahao goodwill impairmentThird major Jiahao write-down
29 Jan 2026Buyback of up to HK$500m from cash reserves announcedCapital return
2 Feb 2026Shares fell more than 10% to about HK$4.58Market reaction
Feb 20261.495m shares repurchased at HK$4.42–4.70Buyback execution
11 Feb 2026Arbitration award of about RMB450.6m in favour of Huabao Flavours against the Shanghai Yifang vendorsPotential recovery; collectability uncertain
20 Mar 2026FY2025 results: revenue +3.3%, attributable loss RMB388.8m, OCF +21.5%, special dividend HK5.5c; IPO project timelines extendedUnderlying earnings down; cash strong
20 Mar 2026Huabao Flavours reports FY2025 net profit of about RMB83.8m (PRC GAAP), a turnaroundListed subsidiary recovery
25 Mar 2026Shares up more than 10% to HK$4.53; discloseable transaction for further financial product subscriptionsTreasury activity
Mar 2026Overseas sales department set up for nutrition and healthHealth internationalisation
10 Apr 20262025 Annual Report and 2025 ESG Report publishedFilings
14 Apr 2026Shanghai First Intermediate People's Court accepts enforcement of the arbitration awardRecovery process
Apr 2026Shandong Jiacui Jinan health base starts production (Phase I)Capacity
7 May 2026Public comment period closes on China's mandatory national standards for heated cigarettes and nicotine pouchesPossible opening of the domestic HNB market
11 May 2026AGM; general mandates to repurchase and issue shares—
May–Jun 20264.79m shares repurchased at HK$3.18–3.88Shares at multi-year lows
15 Jun 2026Huabao Flavours & Fragrances renamed Huabao Technology Co., Ltd.Strategic rebrand
Jun 2026FY2025 special dividend paid (HK$177.5m)—
1H2026Middle East geopolitical conflict halts core tobacco customers' productionTobacco revenue −16.4%
End-Jul 2026Construction of new Jiafu factory beginsCapacity for overseas and hot-pot products
26 Aug 20261H2026 results: revenue +15.9%, operating profit +17.4%, attributable profit −11.7%; HK1.2c plus HK4.08c dividendsGrowth inflection
26 Aug 2026Huabao Technology 1H2026: revenue RMB729.1m, attributable net profit RMB110.0m (PRC GAAP)Subsidiary strength
2 Oct 2026Monthly return: 3,221,640,876 shares in issueNet cancellation of about 8.3m shares since 2025
8 Oct 20261H2026 interim and special dividends paid—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 3,882.7 Mn in FY2021 to CNY 3,484.7 Mn in FY2025.
Huabao International Holdings Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue3,882.73,8293,307.83,373.33,484.7
Gross profit2,296.71,877.61,469.41,441.41,423.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.